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Abstract
Background:  Reserpine, an alkaloid from Rauwolfia serpentina was widely used for its
antihypertensive action in the past. In later years, its use has been reduced because of precipitation
of depression and extra pyramidal symptoms due to its central action. In the present investigation,
reserpine methonitrate (RMN), a novel quaternary analogue of reserpine was synthesised and
evaluated biochemically for its central and peripheral amine depleting actions in rats while its
influence on the blood pressure was measured in anaesthetized rats in comparison with reserpine
Results: Reserpine treatment (5 mg/kg) produced a significant increase in the urinary excretion of
VMA, 5-HIAA and HVA while RMN at doses of equal to and double the equimolar doses of
reserpine (5 and 10 mg/kg) produced significant increase in VMA and 5-HIAA excretion without
producing any effect on HVA excretion compared to control animals. Reserpine in the dose range
of 0.5 to15 µg/kg produced significant reduction in blood pressure compared to control. RMN was
also found to produce significant decrease in blood pressure at doses of 10, 25 and 50 µg/kg body
weight in comparison to control. The results indicated peripheral depletion of biogenic amines by
RMN without affecting the central stores of the amines.
Conclusions: The present study clearly indicated that the quaternization of reserpine restricts its
transfer across the blood-brain barrier and could be the reason for its selective peripheral action.
It is also clear that the hypotensive actions of RMN could be due to peripheral depletion of
catecholamines.
Background
Reserpine, an alkaloid isolated from Rauwolfia  species,
was introduced for the treatment of hypertension and
schizophrenia in 1950's but was replaced by more effec-
tive drugs by the end of 1970's [1-6]. Reserpine is known
to act centrally as well as peripherally by depletion of bio-
genic amines like noradrenaline, dopamine and serot-
onin. Mostly, its peripheral depletion of amines is
Published: 16 November 2004
BMC Pharmacology 2004, 4:30 doi:10.1186/1471-2210-4-30
Received: 28 February 2004
Accepted: 16 November 2004
This article is available from: http://www.biomedcentral.com/1471-2210/4/30
© 2004 Nammi et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Pharmacology 2004, 4:30 http://www.biomedcentral.com/1471-2210/4/30
Page 2 of 7
(page number not for citation purposes)
responsible for its antihypertensive effect while its central
depletion of amines is responsible for its antipsychotic
action [7-13]. However, because of its central action it
produces sedation and Parkinsonism when used for the
management of hypertension for prolonged periods [14-
17]. As a result it has reduced usage for chronic treatment
in hypertensive patients and its use is limited to selective
patient population only [18,19]. Hence there is a need for
structural modification of the drug to make it more
acceptable therapeutically for the treatment of
hypertension.
Attempts were made in the past to synthesize derivatives
of reserpine with possibly higher and/or modified activi-
ties or with fewer side effects [20-23]. Compared to reser-
pine itself, a number of reserpine analogues were found to
exert a stronger influence on the amine concentration in
the periphery than in brain [24-26].
Based on the poor ability of quaternary compounds to
penetrate the blood-brain barrier, a great deal of research
has been devoted towards quaternization of existing drugs
to achieve preferential peripheral action [27-32]. Earlier
reports have demonstrated the synthesis of quaternary
derivatives of reserpine and isoreserpine, however their
pharmacology was not studied [33,34]. Previous studies
by our group also revealed that reserpine methiodide pro-
duced selective depletion of peripheral biogenic amines
without affecting their central stores [35]. In the present
investigation, a quaternary analogue of reserpine viz.,
reserpine methonitrate (RMN), which was synthesized in
our laboratory was evaluated in rats for its amine deplet-
ing actions compared to reserpine. For this, the urinary
levels of vanillylmandelic acid (VMA), 5-hydroxyin-
doleacetic acid (5-HIAA) and homovanillic acid (HVA)
which are the respective metabolites of noradrenaline,
serotonin and dopamine were estimated after reserpine or
RMN treatment in rats. The change in the blood pressure
response of anaesthetized rats after treatment with RMN
was also evaluated in comparison to reserpine.
Results
Biochemical estimations
The main aim of the study was to determine whether
RMN was able to deplete the central and peipheral bio-
genic amines to the same extent as produced by reserpine.
Reserpine at a dose of 5 mg/kg body weight produced sig-
nificant increase in the urinary excretion profile of VMA
compared to control animals. The analogue at doses equi-
molar to reserpine of 5 and 10 mg/kg body weight pro-
duced more significant increase in VMA excretion
compared to controls and that observed with reserpine
(Fig 1). However, the higher dose (10 mg/kg body weight)
of RMN did not further enhance the excretion of VMA
produced by 5 mg/kg body weight dose.
Significant increase in 5-HIAA excretion was observed
with reserpine at a dose of 5 mg/kg body weight and with
the equivalent dose of RMN (Fig 2). The amount of 5-
HIAA excreted in animals treated with the analogue/reser-
Diagram illustrating the effect of reserpine and reserpine  methonitrate on the 24 h urinary excretion of VMA in rats Figure 1
Diagram illustrating the effect of reserpine and 
reserpine methonitrate on the 24 h urinary excretion 
of VMA in rats. Each bar indicates the mean excretion of 
six animals. Significant difference from control group: *p < 
0.05 Significant difference from reserpine treated group: #p < 
0.05 NS-No significant difference between 5 and 10 mg/kg 
treated groups of reserpine methonitrate
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Diagram illustrating the effect of reserpine and reserpine  methonitrate on the 24 h urinary excretion of 5-HIAA in rats Figure 2
Diagram illustrating the effect of reserpine and 
reserpine methonitrate on the 24 h urinary excretion 
of 5-HIAA in rats. Each bar indicates the mean excretion 
of six animals. Significant difference from control group: *p < 
0.05 Significant difference from reserpine treated group: # p 
< 0.05 NS-No significant difference between 5 and 10 mg/kg 
treated groups of reserpine methonitrate
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pine was found to be more than in the control. However
the effect was found to be more with analogue compared
to reserpine. The enhancement in dose to 10 mg/kg body
weight of RMN did not produce any further increase in 5-
HIAA excretion.
A marked increase in the HVA excretion was observed in
animals treated with reserpine compared to controls
while minor change was observed in animals treated with
RMN at doses of 5 and 10 mg/kg body weight compared
to control (Fig 3).
Effect on normal blood pressure of anaesthetized rats
The effect of reserpine and RMN on the normal blood
pressure of anaesthetized rats was shown in Table 1. Dose
dependent hypotension was observed with reserpine as
well as with RMN. However, the vehicle (DMSO) also
produced hypotension which was approximately 15 mm
Hg from basal level. Reserpine at doses of 0.5, 1, 5, 10 and
15  µg/kg produced significant (p < 0.01) reduction in
blood pressure compared to control. RMN was also found
to produce significant (p < 0.01) decrease in blood
pressure at doses of 10, 25 and 50 µg/kg body weight com-
pared to control
Discussion
The structural modification of existing drugs to achieve
selective action is not uncommon in providing better
pharmaceutical care to the needy patients. It has been well
established that the antihypertensive and tranquilizing
actions of reserpine are mediated through the depletion of
biogenic amines in the body [12,13,36]. The peripheral
depletion of amines is responsible for its antihypertensive
effect [11,37] while their central depletion plays a role in
sedation and depression of reserpine [38,39]. Reserpine
exerts its depleting effect by specifically inhibiting the ade-
nosine triphosphate-Mg2+-dependent incorporation of
biogenic amines into their storage vesicles [40,41].
Table 1: Effect of reserpine and reserpine methonitrate on the mean arterial pressure of anaesthetized rats.
Drug Dose (µg/kg) Mean arterial pressure (mmHg, n = 6) Reduction due to drug
Before drug After drug Mean reduction
Vehicle 0.05 ml 126.2 ± 2.8 110.0 ± 4.1 16.2 ± 1.4 ---
Reserpine 0.25 138.3 ± 4.6 119.5 ± 4.2 18.8 ± 1.4NS 2.6
0.50 134.1 ± 5.5 91.2 ± 5.0 42.9 ± 0.9** 26.5
1 135.2 ± 4.7 80.5 ± 3.8 54.8 ± 1.6** 38.6
5 130.5 ± 5.1 69.0 ± 3.5 61.5 ± 2.8** 45.3
10 130.0 ± 4.2 58.7 ± 3.9 71.2 ± 1.3** 55.0
15 131.5 ± 5.1 41.1 ± 2.9 90.4 ± 3.1** 74.2
Reserpine methonitrate equivalent 
to reserpine
10 128.8 ± 6.4 90.0 ± 9.1 38.8 ± 3.6** 22.6
25 135.0 ± 8.5 73.0 ± 7.4 62.0 ± 2.8** 45.8
50 136.8 ± 5.3 42.5 ± 3.7 93.0 ± 8.0** 76.8
Significant difference from DMSO treated group: **p < 0.01
NS – No significant difference from DMSO treated group.
Diagram illustrating the effect of reserpine and reserpine  methonitrate on the 24 h urinary excretion of HVA in rats Figure 3
Diagram illustrating the effect of reserpine and 
reserpine methonitrate on the 24 h urinary excretion 
of HVA in rats. Each bar indicates the mean excretion of 
six animals. Significant difference from control group: *p < 
0.05 Significant difference from reserpine treated group: # p 
< 0.05 NS-No significant difference between 5 and 10 mg/kg 
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Since reserpine depletes noradrenaline, 5-HT and
dopamine from their storage sites, this results in a conse-
quent increase in their metabolite levels in urine. Previous
investigators have demonstrated a marked increase in the
urinary excretion of peripheral and central metabolites of
biogenic amines in animals treated with reserpine [8,42-
44].
In the present investigation, a non-invasive biochemical
approach was followed to determine the 24 h urinary
excretion of VMA, 5-HIAA and HVA in rats treated with
reserpine or RMN. Moreover, VMA, the peripheral
metabolite of noradrenaline; 5-HIAA, the main metabo-
lite of serotonin; and HVA, the predominant metabolite
of dopamine were selected as the biomarkers for evalua-
tion since noradrenaline exists both centrally and periph-
erally, serotonin exists mainly peripherally while majority
of dopamine exists centrally. Since 99% of the total body's
content of serotonin is present in the periphery, it is con-
sidered that the major part of the excreted 5-HIAA is from
the peripheral release [45,46]. Similarly, high levels of
dopamine are found in the centre rather than periphery,
and any change in the HVA excretion in urine was consid-
ered as a corresponding change in dopamine levels at the
central regions [47]. These indices provide an indirect evi-
dence for the peripheral and central monoamine deplet-
ing effects of reserpine and its quaternary analogue.
The results showed that reserpine increased the urinary
excretion of VMA, 5-HIAA and HVA indicating the deple-
tion of peripheral as well as central biogenic amines.
These are in agreement with the results observed by previ-
ous investigators [8,35,42-44]. The increase in the urinary
excretion of VMA and 5-HIAA with RMN is higher than
with reserpine at equimolar dose of 5 mg/kg body weight.
The localized distribution of the analogue in the
periphery could led to higher level of depletion of periph-
eral noradrenaline and serotonin hence their metabolite
levels were found to be increased much more which also
substantiate our previous studies [35]. The inability of the
analogue to increase HVA excretion unlike reserpine
could be due to its non-entry across the blood-brain bar-
rier and into the central nervous system to deplete
dopamine which is present predominantly in mesolim-
bic, nigrostriatal and tuberoinfendibular systems [48].
The increased urinary levels of 5-HIAA observed with
RMN could be due to the peripheral release of 5-HT as it
is found predominantly at the periphery in enterochroma-
ffin cells. The higher dose (10 mg/kg) of RMN did not pro-
duce any further increase in the VMA and 5-HIAA
excretion compared to lower dose. The possible reason for
this effect could be that 5 mg/kg dose was sufficient to
deplete the amines completely from the storage sites.
In order to evaluate whether the quaternary analogue of
reserpine (RMN) still retains the peripheral blood pres-
sure lowering activity, further experiments were carried
out on the blood pressure of anaesthetized rats. Thus far,
the results of RMN on the blood pressure response of
anaesthetized rats confirmed that the peripheral actions of
reserpine molecule are not affected by quaternization.
However, in the present study the vehicle (DMSO) also
produced minor hypotensive effect on blood pressure of
rats when administered alone with the dose used for the
administration of the drugs. Earlier workers [49] also
reported hypotension with DMSO supporting the present
observations. Reserpine produced dose dependent reduc-
tion in blood pressure as demonstrated by previous inves-
tigators [50,51]. As indicated in earlier reports
[9,11,40,52-54] the hypotensive effect of reserpine
observed in rats is due to the depletion of catecholamines
from the peripheral stores.
The effect of equimolar doses of RMN also indicated
hypotension however, with higher doses compared to
reserpine. It is further indicated that quaternization of
reserpine not only restricted the entry of RMN to central
nervous system but also reduced to the target tissue in the
periphery. Hence relatively higher doses were required to
produce reserpine like effect. Mechanistically, the hypo-
tensive actions of RMN could also be due to peripheral
depletion of catecholamines as evident from the positive
correlation with the results of previous section on the
peripheral depletion of monoamines.
Conclusion
In conclusion, the present study indicated that the quater-
nization of reserpine molecule prevents its access into the
central nervous system and thereby produces selective
peripheral depletion of biogenic amines. Furthermore,
the study indicated that quaternization of reserpine had
not abolished the hypotensive response but only higher
doses were required.
Methods
Chemistry
The synthesis of RMN was done as follows: The solution
of reserpine (2 g, 3.3 mmols) in dichloromethane (20 ml)
was added to methyl iodide (11 ml, 176 mmols) and the
resulting mixture was kept for two days in dark. The solid
was filtered and washed with a little cold dichlorometh-
ane and dried under vacuum at 70°C for 2 h to yield reser-
pine methiodide (RMI) [33,34]. Then, to a solution of
RMI (0.25 gm, 0.67 mmols) in a mixture of dichlo-
romethane (3 ml) and aqueous ethanol (90%, 2 ml) was
added a solution of silver nitrate (56 mg, 0.67 mmols) in
aqueous ethanol (90%, 2 ml). The reaction mixture was
stirred overnight at room temperature. The solution was
filtered and washed thoroughly with chloroform : metha-BMC Pharmacology 2004, 4:30 http://www.biomedcentral.com/1471-2210/4/30
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nol (1:1). The solid obtained after evaporation of the sol-
vent was passed through a silica gel column and eluted
with chloroform : methanol (80:20) to yield RMN, m.p.
292–294°C.
Chemicals used
Reserpine and thiopentone were generous gift samples
from Novartis India Limited and Abbott Laboratories,
Mumbai respectively. The standard samples of VMA, 5-
HIAA, HVA and iso-VMA (internal standard) were pur-
chased from Sigma-Aldrich, St. Louis, USA. All other
chemicals used were of HPLC or analytical grade as
appropriate.
The solutions of reserpine and RMN under study were pre-
pared in DMSO and the volume of each dose was adjusted
to 0.1 ml/100 gm body weight as suggested by Varma et
al., [49]. The doses of RMN were calculated on equimolar
basis of reserpine.
Animal experiments
Albino rats of either sex weighing between 100–150 gm
(Charkaborty Enterprise, Kolkata) were used in the study.
They were acclimatized to the laboratory conditions for at
least 10 days prior to the experiment and were provided
with standard diet and water ad libitum with 12 h light and
dark cycle. The animal experiments conducted in this
research work were approved by the Institutional Animal
Ethics Committee and by the government regulatory body
for animal research (Regd. No. 516/01/A/CPCSEA).
Biochemical estimations
Animals were divided into 4 groups of six each and were
housed individually in metabolic cages. Funnels of suita-
ble size were arranged at the bottom of the metabolic
cages for collection of urine. Perforated plastic discs were
arranged in the funnels to retain fecal matter. The animals
were maintained at room temperature and acclimatized to
metabolic cages for few days prior to drug administration.
The treatment given to the groups of animals was as
follows:
Group 1: Control animals treated with DMSO intraperito-
neally at a dose of 0.1 ml/100 gm body weight.
Group 2: Animals administered intraperitoneally with
reserpine at a dose of 5 mg/kg body weight.
Group 3: Animals administered intraperitoneally with
RMN at a dose equivalent to 5 mg/kg body weight of
reserpine.
Group 4: Animals administered intraperitoneally with
RMN at a dose equivalent to 10 mg/kg body weight of
reserpine.
In each group, animals were placed individually in meta-
bolic cages after drug administration and were allowed
access to water. The 24 h urine samples from the point of
drug administration was collected for each animal in a
beaker containing 5 ml of 6 M HCl arranged at the bottom
of the funnel. The volumes of the 24 h urine samples col-
lected in the beakers were noted individually and about 2
ml of urine (mixture) from each animal was taken into
sample tubes and centrifuged at 3000 rpm for 10 minutes.
The supernatants were transferred into another set of
clean and dry tubes and stored at -20°C until analysis by
HPLC.
Simultaneous HPLC determination of VMA, 5-HIAA and HVA in urine
The procedure described by Wako-chem. Co.,[55] was
used for the simultaneous determination of the above
metabolites. The urine samples were thawed before anal-
ysis. To 0.2 ml of each sample, 0.1 ml of internal standard
(iso-VMA, 1000 ηg) and 0.7 ml of mobile phase were
added. The solutions were mixed well and filtered
through 0.4 µm membrane filter. The filtrate (20 µL) was
injected into the column (RP C-18, 250 mm × 4.6 mm
I.D; particle size 5 µm; YMC Inc., USA). The mobile phase
(filtered through 0.4 µm membrane filter) comprised of
10:90 v/v of acetonitrile and 0.1 M KH2PO4 and the flow
rate of the mobile phase was maintained at 0.8 ml/min,
which yields a column back pressure of 220–230 kgf/cm2.
Detection was done by UV absorption at 230 ηm. The
range of the detector was set at 0.001 a.u.f.s. The peak area
ratios of VMA, 5-HIAA and HVA to that of internal stand-
ard were calculated and substituted in the respective
regression equations to estimate the amount of the
metabolite present in the sample.
Effect on normal blood pressure of anaesthetized rats
The procedure described by Noble [56] was followed to
evaluate the effect of RMN on normal blood pressure of
anaesthetized rats in comparison with reserpine. Groups
of rats of six each were anaesthetized with an intraperito-
neal injection of thiopentone (40 mg/kg body weight).
The femoral vein was cannulated for administration of
supplementary doses of anaesthetic (if required) and drug
solutions.
Haemodynamic setup was used to record the blood pres-
sure of rats. The blood pressure of each animal was
recorded from left common carotid artery connected to a
mercury manometer on kymograph paper. The normal
blood pressure of rats was recorded after stabilization for
30 minutes. The different doses of reserpine (0.25, 0.50,
1, 5, 10 and 15 µg/kg body weight) or RMN (10, 25 andBMC Pharmacology 2004, 4:30 http://www.biomedcentral.com/1471-2210/4/30
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50 µg/kg body weight) were studied in separate groups (n
= 6) to determine the change in blood pressure response.
Statistical analysis
Data are expressed as mean ± standard error of means. Sta-
tistical analysis was done using one-way analysis of vari-
ance (ANOVA). Post-hoc comparisons were done by
using Dunnet's t-test. In all the cases, p < 0.05 was consid-
ered statistically significant.
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RMN: Reserpine methonitrate
VMA: Vanillylmandelic acid
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HVA: Homovanillic acid
DMSO: Dimethyl sulfoxide
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